Advertisement

Selective non-operative management of distal rectal cancer: The Watch & Wait Protocol

  • Angelita Habr-GamaEmail author
  • Rodrigo O. Perez
  • Patricio B. Lynn
  • Guilherme Pagin São Julião
  • Joaquim José Gama Rodrigues

Abstract

The observation of improved local disease control with the use of preoperative chemoradiation (CRT) for locally advanced rectal cancer established this treatment strategy as one the preferred initial approaches for this disease. Interestingly, the benefits of preoperative CRT were not restricted to local recurrence rates but also included reduced toxicity rates compared to postoperative CRT, significant tumor downstaging and downsizing, greater rates of sphincter preservation, and better functional results [1, 2].

Keywords

Rectal Cancer Radiat Oncol Biol Phys Transanal Endoscopic Microsurgery Advanced Rectal Cancer Preoperative Chemoradiation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Habr-Gama A, Perez RO, Kiss DR, Rawet V, Scanavini A, Santinho PM, Nadalin W (2004) Preoperative chemoradiation therapy for low rectal cancer. Impact on downstaging and sphincter-saving operations. Hepato-gastroenterol 51(60): 1703–1707Google Scholar
  2. [2]
    Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351(17): 1731–1740PubMedCrossRefGoogle Scholar
  3. [3]
    Chessin DB, Enker W, Cohen AM, Paty PB, Weiser MR, Saltz L, Minsky BD, Wong WD, Guillem JG (2005) Complications after preoperative combined modality therapy and radical resection of locally advanced rectal cancer: a 14-year experience from a specialty service. JAmColl Surg 200(6): 876–882; discussion 82–84Google Scholar
  4. [4]
    Matthiessen P, Hallbook O, Andersson M, Rutegard J, Sjodahl R (2004) Risk factors for anastomotic leakage after anterior resection of the rectum. Colorectal Dis 6(6): 462–469PubMedCrossRefGoogle Scholar
  5. [5]
    Eriksen MT, Wibe A, Norstein J, Haffner J, Wiig JN (2005) Anastomotic leakage following routine mesorectal excision for rectal cancer in a national cohort of patients. Colorectal Dis 7(1): 51–57PubMedCrossRefGoogle Scholar
  6. [6]
    Perez RO, Habr-Gama A, Seid VE, Proscurshim I, Sousa AH Jr, Kiss DR, Linhares M, Sapucahy M, Gama-Rodrigues J (2006) Loop ileostomy morbidity: timing of closure matters. Dis Colon Rectum 49(10): 1539–1545PubMedCrossRefGoogle Scholar
  7. [7]
    Denost Q, Laurent C, Capdepont M, Zerbib F, Rullier E (2011) Risk factors for fecal incontinence after intersphincteric resection for rectal cancer. Dis Colon Rectum 54(8): 963–968PubMedCrossRefGoogle Scholar
  8. [8]
    Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Saltz LB, Goodman KA, Minsky BD, Wong WD, Weiser MR (2008) Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer 113(1): 57–64PubMedCrossRefGoogle Scholar
  9. [9]
    Maas M, Nelemans PJ, Valentini V, Das P, Rodel C, Kuo LJ, Calvo FA, Garcia-Aguilar J, Glynne-Jones R, Haustermans K, Mohiuddin M, Pucciarelli S, Small W Jr, Suarez J, Theodoropoulos G, Biondo S, Beets-Tan RG, Beets GL (2010) Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 11(9): 835–844PubMedCrossRefGoogle Scholar
  10. [10]
    Hiotis SP, Weber SM, Cohen AM, Minsky BD, Paty PB, Guillem JG, Wagman R, Saltz LB, Wong WD (2002) Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg 194(2): 131–135; discussion 5–6CrossRefGoogle Scholar
  11. [11]
    Habr-Gama A, Perez RO, Wynn G, Marks J, Kessler H, Gama-Rodrigues J (2010) Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum 53(12): 1692–1698PubMedCrossRefGoogle Scholar
  12. [12]
    Mezzi G, Arcidiacono PG, Carrara S, Perri F, Petrone MC, De Cobelli F, Gusmini S, Staudacher C, Del Maschio A, Testoni PA (2009) Endoscopic ultrasound and magnetic resonance imaging for re-staging rectal cancer after radiotherapy. World J Gastroenterol 15(44): 5563–5567PubMedCrossRefGoogle Scholar
  13. [13]
    Suppiah A, Hunter IA, Cowley J, Garimella V, Cast J, Hartley JE, Monson JR (2009) Magnetic resonance imaging accuracy in assessing tumour down-staging following chemoradiation in rectal cancer. Colorectal Dis 11(3): 249–253PubMedCrossRefGoogle Scholar
  14. [14]
    Kim YH, Kim DY, Kim TH, Jung KH, Chang HJ, Jeong SY, Sohn DK, Choi HS, Ahn JB, Kim DH, Lim SB, Lee JS, Park JG (2005) Usefulness of magnetic resonance volumetric evaluation in predicting response to preoperative concurrent chemoradiotherapy in patients with resectable rectal cancer. Int J Radiat Oncol Biol Phys 62(3): 761–768PubMedCrossRefGoogle Scholar
  15. [15]
    Kang JH, Kim YC, Kim H, Kim YW, Hur H, Kim JS, Min BS, Kim H, Lim JS, Seong J, Keum KC, Kim NK (2010) Tumor volume changes assessed by three-dimensional magnetic resonance volumetry in rectal cancer patients after preoperative chemoradiation: the impact of the volume reduction ratio on the prediction of pathologic complete response. Int J Radiat Oncol Biol Phys 76(4): 1018–1025PubMedCrossRefGoogle Scholar
  16. [16]
    Lambregts DM, Vandecaveye V, Barbaro B, Bakers FC, Lambrecht M, Maas M, Haustermans K, Valentini V, Beets GL, Beets-Tan RG (2011) Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study. Ann Surg Oncol 18(8): 2224–2231PubMedCrossRefGoogle Scholar
  17. [17]
    Curvo-Semedo L, Lambregts DM, Maas M, Thywissen T, Mehsen RT, Lammering G, Beets GL, Caseiro-Alves F, Beets-Tan RG (2011) Rectal cancer: assessment of complete response to preoperative combined radiation therapy with chemotherapy — Conventional MR volumetry versus diffusion-weighted MR imaging. Radiology 260(3): 734–743CrossRefGoogle Scholar
  18. [18]
    Calvo FA, Domper M, Matute R, Martinez-Lazaro R, Arranz JA, Desco M, Alvarez E, Carreras JL (2004) 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 58(2): 528–535PubMedCrossRefGoogle Scholar
  19. [19]
    Guillem JG, Puig-La Calle J Jr, Akhurst T, Tickoo S, Ruo L, Minsky BD, Gollub MJ, Klimstra DS, Mazumdar M, Paty PB, Macapinlac H, Yeung H, Saltz L, Finn RD, Erdi Y, Humm J, Cohen AM, Larson S (2000) Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum 43(1): 18–24PubMedCrossRefGoogle Scholar
  20. [20]
    Kristiansen C, Loft A, Berthelsen AK, Graff J, Lindebjerg J, Bisgaard C, Jakobsen A (2008) PET/CT and histopathologic response to preoperative chemoradiation therapy in locally advanced rectal cancer. Dis Colon Rectum 51(1): 21–25PubMedCrossRefGoogle Scholar
  21. [21]
    Perez RO, Habr-Gama A, Julião GPS, Gama-Rodrigues J, Proscurshim I, Lynn P, Ono C, Campos F, Sousa Jr. AS, Imperiale A, Nahas S, Buchpiguel C (2011) Accuracy of PET/CT and clinical assessment in the detection of complete rectal tumor regression following neoadjuvant chemoradiation. Long-term results of a prospective trial (NCT00254683). Cancer (in press)Google Scholar
  22. [22]
    Moreno Garcia V, Cejas P, Blanco Codesido M, Feliu Batlle J, de Castro Carpeno J, Belda-Iniesta C, Barriuso J, Sanchez JJ, Larrauri J, Gonzalez-Baron M, Casado E (2009) Prognostic value of carcinoembryonic antigen level in rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Colorectal Dis 24(7): 741–748PubMedCrossRefGoogle Scholar
  23. [23]
    Kim CW, Yu CS, Yang SS, Kim KH, Yoon YS, Yoon SN, Lim SB, Kim JC (2011) Clinical significance of pre-to postchemoradiotherapy s-CEA reduction ratio in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection. Ann Surg Oncol 18(2): 3271–3277PubMedCrossRefGoogle Scholar
  24. [24]
    Jang NY, Kang SB, Kim DW, Kim JH, Lee KW, Kim IA, Kim JS (2011) The role of carcinoembryonic antigen after neoadjuvant chemoradiotherapy in patients with rectal cancer. Dis Colon Rectum 54(2): 245–252PubMedCrossRefGoogle Scholar
  25. [25]
    Perez RO, Habr-Gama A, São Julião GP, Proscurshim I, Kiss DR, Gama-Rodrigues J, Cecconello I (2009) The role of CEA in predicting response and survival to neoadjuvant CRT for distal rectal cancer. Dis Colon Rectum (in press)Google Scholar
  26. [26]
    Meterissian S, Skibber J, Rich T, Roubein L, Ajani J, Cleary K, Ota DM (1994) Patterns of residual disease after preoperative chemoradiation in ultrasound T3 rectal carcinoma. Ann Surg Oncol 1(2): 111–116PubMedCrossRefGoogle Scholar
  27. [27]
    Perez RO (2011) The role of biopsies in patients with residual rectal cancer following neoadjuvant chemoradiation after downsizing: can they rule out persisting cancer? Colorectal Dis (in press)Google Scholar
  28. [28]
    Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M (2006) Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93(10): 1215–1223PubMedCrossRefGoogle Scholar
  29. [29]
    Bosset JF, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Briffaux A, Collette L (2005) Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results — EORTC 22921. J Clin Oncol 23(24): 5620–5627PubMedCrossRefGoogle Scholar
  30. [30]
    Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355(11): 1114–1123PubMedCrossRefGoogle Scholar
  31. [31]
    Sanghera P, Wong DW, McConkey CC, Geh JI, Hartley A (2008) Chemoradiotherapy for rectal cancer: an updated analysis of factors affecting pathological response. Clin Oncol (R Coll Radiol) 20(2): 176–183CrossRefGoogle Scholar
  32. [32]
    Gerard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, Vendrely V, Francois E, de La Roche G, Bouche O, Mirabel X, Denis B, Mineur L, Berdah JF, Mahe MA, Becouarn Y, Dupuis O, Lledo G, Montoto-Grillot C, Conroy T (2010) Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 28(10): 1638–1644PubMedCrossRefGoogle Scholar
  33. [33]
    Weiss C, Arnold D, Dellas K, Liersch T, Hipp M, Fietkau R, Sauer R, Hinke A, Rodel C (2010) Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: a pooled analysis of three prospective phase I-II trials. Int J Radiat Oncol Biol Phys 78(2): 472–478PubMedCrossRefGoogle Scholar
  34. [34]
    Glynne-Jones R, Mawdsley S, Harrison M (2010) Cetuximab and chemoradiation for rectal cancer — is the water getting muddy? Acta Oncol 49(3): 278–286PubMedCrossRefGoogle Scholar
  35. [35]
    Francois Y, Nemoz CJ, Baulieux J, Vignal J, Grandjean JP, Partensky C, Souquet JC, Adeleine P, Gerard JP (1999) Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphinctersparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 17(8): 2396PubMedGoogle Scholar
  36. [36]
    Moore HG, Gittleman AE, Minsky BD, Wong D, Paty PB, Weiser M, Temple L, Saltz L, Shia J, Guillem JG (2004) Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum 47(3): 279–286PubMedCrossRefGoogle Scholar
  37. [37]
    Tulchinsky H, Shmueli E, Figer A, Klausner JM, Rabau M (2008) An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and diseasefree survival in patients with locally advanced rectal cancer. Ann Surg Oncol 15(10): 2661–2667PubMedCrossRefGoogle Scholar
  38. [38]
    Kalady MF, de Campos-Lobato LF, Stocchi L, Geisler DP, Dietz D, Lavery IC, Fazio VW (2009) Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg 250(4): 582–589PubMedGoogle Scholar
  39. [39]
    Garcia-Aguilar J, Smith DD, Avila K, Bergsland EK, Chu P, Krieg RM (2011) Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg 254(1): 97–102PubMedCrossRefGoogle Scholar
  40. [40]
    Withers HR, Haustermans K (2004) Where next with preoperative radiation therapy for rectal cancer? Int J Radiat Oncol Biol Phys 58(2): 597–602PubMedCrossRefGoogle Scholar
  41. [41]
    Kerr SF, Norton S, Glynne-Jones R (2008) Delaying surgery after neoadjuvant chemoradiotherapy for rectal cancer may reduce postoperative morbidity without compromising prognosis. Br J Surg 95(12): 1534–1540PubMedCrossRefGoogle Scholar
  42. [42]
    Habr-Gama A, Perez RO, Proscurshim I, Nunes Dos Santos RM, Kiss D, Gama-Rodrigues J, Cecconello I (2008) Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: does delayed surgery have an impact on outcome? Int J Radiat Oncol Biol Phys 71(4): 1181–1188PubMedCrossRefGoogle Scholar
  43. [43]
    Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Wolff RA, Eng C, Krishnan S, Janjan NA, Crane CH (2007) Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer 109(9): 1750–1755PubMedCrossRefGoogle Scholar
  44. [44]
    Ghadimi BM, Grade M, Difilippantonio MJ, Varma S, Simon R, Montagna C, Fuzesi L, Langer C, Becker H, Liersch T, Ried T (2005) Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 23(9): 1826–1838PubMedCrossRefGoogle Scholar
  45. [45]
    Kim IJ, Lim SB, Kang HC, Chang HJ, Ahn SA, Park HW, Jang SG, Park JH, Kim DY, Jung KH, Choi HS, Jeong SY, Sohn DK, Kim DW, Park JG (2007) Microarray gene expression profiling for predicting complete response to preoperative chemoradiotherapy in patients with advanced rectal cancer. Dis Colon Rectum 50(9): 1342–1353PubMedCrossRefGoogle Scholar
  46. [46]
    Rimkus C, Friederichs J, Boulesteix AL, Theisen J, Mages J, Becker K, Nekarda H, Rosenberg R, Janssen KP, Siewert JR (2008) Microarray-based prediction of tumor response to neoadjuvant radiochemotherapy of patients with locally advanced rectal cancer. Clin Gastroenterol Hepatol 6(1): 53–61PubMedCrossRefGoogle Scholar
  47. [47]
    Perez RO (2011) Predicting response to neoadjuvant treatment for rectal cancer: a step toward individualized medicine. Dis Colon Rectum 54(9): 1057–1058PubMedCrossRefGoogle Scholar
  48. [48]
    Garcia-Aguilar J, Chen Z, Smith DD, Li W, Madoff RD, Cataldo P, Marcet J, Pastor C (2011) Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. Ann Surg 254(3): 486–493PubMedCrossRefGoogle Scholar
  49. [49]
    Habr-Gama A, de Souza PM, Ribeiro U Jr, Nadalin W, Gansl R, Sousa AH Jr, Campos FG, Gama-Rodrigues J (1998) Low rectal cancer: impact of radiation and chemotherapy on surgical treatment. Dis Colon Rectum 41(9): 1087–1096PubMedCrossRefGoogle Scholar
  50. [50]
    Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U Jr, Silvae Sousa AH Jr, Campos FG, Kiss DR, Gama-Rodrigues J (2004) Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: longterm results. Ann Surg 240(4): 711–717; discussion 7–8PubMedGoogle Scholar
  51. [51]
    Habr-Gama A, Perez RO, Proscurshim I, Campos FG, Nadalin W, Kiss D, Gama-Rodrigues J (2006) Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg 10(10): 1319–1328; discussion 28–29PubMedCrossRefGoogle Scholar
  52. [52]
    Habr-Gama A, Perez RO, Sabbaga J, Nadalin W, Sao Juliao GP, Gama-Rodrigues J (2009) Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period. Dis Colon Rectum 52(12): 1927–1934PubMedCrossRefGoogle Scholar
  53. [53]
    Chua YJ, Barbachano Y, Cunningham D, Oates JR, Brown G, Wotherspoon A, Tait D, Massey A, Tebbutt NC, Chau I (2010) Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol 11(3): 241–248PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2012

Authors and Affiliations

  • Angelita Habr-Gama
    • 1
    Email author
  • Rodrigo O. Perez
    • 1
    • 2
  • Patricio B. Lynn
    • 1
  • Guilherme Pagin São Julião
    • 1
    • 2
  • Joaquim José Gama Rodrigues
    • 1
    • 2
  1. 1.Angelita & Joaquim Gama InstituteSão PauloBrazil
  2. 2.School of MedicineUniversity of Sao PauloSão PauloBrazil

Personalised recommendations